Medical News Update The Breakthrough Wegovy Weight Loss Pill
Artikel konnten nicht hinzugefügt werden
Der Titel konnte nicht zum Warenkorb hinzugefügt werden.
Der Titel konnte nicht zum Merkzettel hinzugefügt werden.
„Von Wunschzettel entfernen“ fehlgeschlagen.
„Podcast folgen“ fehlgeschlagen
„Podcast nicht mehr folgen“ fehlgeschlagen
Medical News Update The Breakthrough Wegovy Weight Loss Pill
-
Gesprochen von:
-
Von:
Über diesen Titel
FDA Approves Wegovy Weight-Loss Pill: What to Know About Oral Semaglutide
This episode explains the first FDA-approved GLP-1 weight-loss drug in pill form: a once-daily oral semaglutide tablet (Wegovy pill) approved on December 22, 2025, with a U.S. launch in early January 2026. It clarifies that Rybelsus is also oral semaglutide but is only approved for type 2 diabetes, making Wegovy the first oral GLP-1 specifically approved for chronic weight management. Results from the 71-week OASIS 4 trial showed average weight loss of 13.6% at a 25 mg dose versus 2.2% with placebo, with adherent patients closer to 16.6%. The script highlights strict dosing requirements (empty stomach, ≤4 oz water, wait 30 minutes), similar nausea side effects to injections, expected similar pricing, and ongoing insurance and adherence hurdles while noting improved access for those avoiding injections.
00:00 Oral Wegovy Arrives
00:35 What Makes It New
00:53 OASIS 4 Results
01:33 How to Take It
01:58 Who Benefits Most
02:28 Caveats and Costs
02:49 Wrap Up